biopharmconsortium.com
Spark Therapeutics’ retinal disease gene therapy SPK-RPE65 may reach the U.S. market in 2017
As we discussed in our November 16, 2015 article on this blog, Spark Therapeutics (Philadelphia, PA) recently announced positive top-line results from the Phase 3 pivotal trial of SPK-RPE65, a gene…